Clinical Trial Update: Xeloda and Bevacizumab to Treat Rectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial tested Xeloda (capecitabine) with bevacizumab for rectal cancer; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Xeloda (capecitabine)

Snippet

Sponsor: Institut Català d'Oncologia | Conditions: Rectal Cancer | Phase 2 | Status: COMPLETED